Home » Authors » Nuala Moran

Articles by Nuala Moran

Vernalis Paying $50M To Regain Frovatriptan Rights From Elan

April 2, 2004

Celltech On Hunt For Partner Following Phase III Trial In RA

April 1, 2004

Celltech On Hunt For Partner Following Phase III Trial In RA

April 1, 2004

Arakis Acquires Sirus, Gains Access To Sublingual Platform

March 31, 2004

Vernalis Paying $50M To Regain Frovatriptan Rights From Elan

March 31, 2004

UK Awards Grants For Work Focused On Disease Genetics

March 31, 2004

Vernalis Paying $50M To Regain Frovatriptan Rights From Elan

March 31, 2004

Arakis Acquires Sirus, Gains Access To Sublingual Platform

March 31, 2004

UK Awards Grants For Work Focused On Disease Genetics

March 31, 2004

Celltech Considering Partners For CDP 870 Co-Development

March 24, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...